Luye Pharma Group (OTCMKTS:LYPHF) is an integrated, research-driven pharmaceutical company headquartered in Yantai, Shandong Province, China. The company’s core business encompasses the research, development, manufacturing, distribution and marketing of prescription and over-the-counter pharmaceutical products. Luye Pharma has built a comprehensive platform that spans early-stage drug discovery through late-stage commercialization, with a focus on delivering innovative therapies to patients in China and abroad.
The company’s therapeutic portfolio targets key disease areas, including oncology, cardiovascular and metabolic disorders, respiratory diseases, central nervous system conditions and anti-infectives. Its product lineup features both small-molecule drugs and complex formulations, alongside a growing pipeline of long-acting treatments and novel chemical entities. In addition to traditional pharmaceuticals, Luye Pharma has expanded into health-management services and digital health solutions designed to support chronic disease management and post-acute care.
Luye Pharma operates multiple state-of-the-art manufacturing facilities across China—located in Yantai, Suzhou and Lanxi—and maintains R&D centers domestically and in Europe. This global footprint enables the company to adhere to international quality standards and accelerate the development of new compounds. Luye Pharma’s distribution network comprises dozens of regional offices in China and partnerships in markets such as Europe, North America and the Asia-Pacific region.
Founded in 1994 and publicly listed on the Hong Kong Stock Exchange in 2006, Luye Pharma Group has grown through organic innovation as well as strategic acquisitions, including the integration of European subsidiaries to bolster its international presence. The company is guided by an experienced management team committed to advancing patient care through scientific excellence and global collaboration.
AI Generated. May Contain Errors.
